PTC Therapeutics (NASDAQ:PTCT) Upgraded by Wall Street Zen to Strong-Buy Rating

Posted by Brian Himes on Aug 2nd, 2026

Wall Street Zen upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a hold rating to a strong-buy rating in a research report released on Saturday.

PTCT has been the topic of several other reports. Raymond James Financial started coverage on shares of PTC Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $108.00 price objective on the stock. Royal Bank Of Canada upped their target price on shares of PTC Therapeutics from $82.00 to $85.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Wells Fargo & Company increased their target price on shares of PTC Therapeutics from $93.00 to $106.00 and gave the stock an “overweight” rating in a research note on Friday. Citigroup raised PTC Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $75.00 to $108.00 in a report on Tuesday, June 9th. Finally, Morgan Stanley boosted their price target on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Check Out Our Latest Research Report on PTC Therapeutics

PTC Therapeutics Trading Down 9.9%

Shares of PTCT opened at $68.01 on Friday. The firm has a market cap of $5.64 billion, a PE ratio of -117.26, a price-to-earnings-growth ratio of 5.92 and a beta of 0.53. The company’s 50 day simple moving average is $77.57 and its 200-day simple moving average is $72.74. PTC Therapeutics has a 12-month low of $43.17 and a 12-month high of $90.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.68. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The business had revenue of $360.52 million for the quarter, compared to analysts’ expectations of $298.63 million. During the same period in the previous year, the company posted ($0.83) EPS. The company’s quarterly revenue was up 101.5% on a year-over-year basis. As a group, equities research analysts forecast that PTC Therapeutics will post 0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric Pauwels sold 21,277 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $75.00, for a total value of $1,595,775.00. Following the completion of the sale, the insider owned 73,411 shares in the company, valued at approximately $5,505,825. This trade represents a 22.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of PTC Therapeutics stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the completion of the sale, the director directly owned 21,813 shares in the company, valued at approximately $1,963,170. The trade was a 42.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 198,662 shares of company stock worth $16,347,994 in the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PTCT. Handelsbanken Fonder AB lifted its position in PTC Therapeutics by 15.1% in the second quarter. Handelsbanken Fonder AB now owns 29,000 shares of the biopharmaceutical company’s stock valued at $2,366,000 after purchasing an additional 3,800 shares during the period. GAMMA Investing LLC increased its position in PTC Therapeutics by 58.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 534 shares during the period. Avior Wealth Management LLC acquired a new position in PTC Therapeutics during the 2nd quarter worth approximately $308,000. Harbor Investment Advisory LLC purchased a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $81,000. Finally, Defilade Capital Management L.P. purchased a new position in shares of PTC Therapeutics during the 1st quarter worth approximately $25,628,000.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.